Docket No.: 0020-5502PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Takamasa WATANABE et al.

Application No.: 10/568,761

Confirmation No.: 6669

Filed: February 21, 2006

Art Unit: 1644

For: PREVENTION OR REMEDY FOR

INFLAMMATORY BOWEL DISEASES CONTAINING ANTI-CD81 ANTIBODY AS

THE ACTIVE INGREDIENT

Examiner: M. M. Haddad

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. <u>LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION</u>

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-SB08(s), attached hereto.

II. <u>COPIES</u>

a. Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.

Application 1	No.: 10/568,761	Docket No.: 0020-5502PUS1
		the PTO-SB08 are not enclosed because copies should already be in the PTO file.
patents, publ	nsideration of information listed on the I ications, or other information which are are not enclosed herewith, were previous ving applications which has been relied	SUBMITTED - Pursuant to 37 C.F.R. PTO-SB08 form(s) is requested since any listed on the PTO-SB08 form(s) but for ly cited by or submitted to the PTO in one upon for an earlier filing date under 35
	CISE EXPLANATION OF THE RELEVA	ANCE
		UAGE – Some or all of the patents, ed PTO SB08 are in the English language
b. relevance of language is as	all patents, publications, or other infor	NGUAGE - A concise explanation of the mation listed that is not in the English
		An English language version of the search found by the foreign office is attached, ation. See MPEP 609(III)(A)(3).
☑ d. consideration	OTHER - The following additional info	ormation is provided for the Examiner's ch Report.
a.	(check one box) This Information Disclosure Statement in application; therefore, no fee is required	s being filed concurrently with the filing

2

DRN/kpc

a cont	b. tinuation	This Information Disclosure Statement is being filed concurrent with the filing of in-in-part, continuation, or divisional patent application; therefore, no fee is required
		This Information Disclosure Statement is being filed within three months of the a national application (37 C.F.R. § 1.97(b)(1)). No fee or statement is required is not to be used with RCE's.)
		This Information Disclosure Statement is being filed within three months of the of the national stage as set forth in § 1.491 in an international application (37 C.F.R. No fee or statement is required.
	e. Request nent is re	This Information Disclosure Statement is being filed concurrently with the filing for Continued Examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or equired.
event C.F.R.	that a fi . § 1.97	This Information Disclosure Statement is being filed before the mailing date of an the merits (37 C.F.R. § 1.97(b)(3)). No fee or statement is required . In the rest Office Action on the merits has been issued, please consider this IDS under 37 (c) and see the statement under 37 C.F.R. § 1.97(e) below, or, if no statement has arge our deposit account for the fee as required by 37 C.F.R. § 1.17(p).
		This Information Disclosure Statement is being filed before the mailing date of a action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c)(1)) or before the mailing see of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c)(2)). No statement; therefore, a fee as required by 37 C.F.R. § 1.17(p) is attached. or See the statement below. No fee is required.
V.	(check	EMENT UNDER 37 C.F.R. § 1.97(e) only one box) dersigned hereby states that:

Application No.: 10/568,761

Docket No.: 0020-5502PUS1

Each item of information contained in the IDS was first cited in any a. communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or b. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or c. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement. VI. PAYMENT OF FEES (check one box) The required fee is listed on the attached Fee Transmittal. X No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the

undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is

4

Application No.: 10/568,761

Docket No.: 0020-5502PUS1

requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Π.	4.		
1 12	łΤє	•(1	•

OCT 3 1 2007 Respectfully submitted,

By wy well
Mark J. Nuell
Registration No.: 36,623
BIRCH, STEWART, KOLASCH & BIRCH, LLP
12770 High Bluff Drive
Suite 260
San Diego, California 92130
(858) 792-8855
Attorney for Applicant

Attach	ment(s):
\boxtimes	PTO/SB/08
\boxtimes	Document(s)
\boxtimes	Supplementary Partial European Search Report
	Fee
	Other: